Global Bruxism Management Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type;

Diurnal Bruxism and Nocturnal Bruxism.

By Drugs Availability;

Over-The-Counter (OTC) and Prescription.

By Cause;

Obstructive Sleep Apnea, Sleep Paralysis, Malocclusion, Gastroesophageal Reflux Disease (GERD), Depression, Anxiety, and Others.

By Distribution Channel;

Institutional Sales, Hospital, Dental Clinic, Retail Sales, Drug Store, Retail Store, Supermarket, and Mail Order Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn903595247 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Bruxism Management Market (USD Million), 2021 - 2031

In the year 2024, the Global Bruxism Management Market was valued at USD 6,308.72 million. The size of this market is expected to increase to USD 10,201.56 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.1%.

The global Bruxism Management Market addresses the challenges posed by bruxism, a condition characterized by excessive teeth grinding or jaw clenching, which can occur during sleep (sleep bruxism) or while awake (awake bruxism). This condition affects individuals of all ages and can lead to various dental, oral, and general health issues if left untreated. Common consequences include dental enamel wear, tooth fractures, jaw pain, temporomandibular joint (TMJ) disorders, headaches, and disrupted sleep patterns.

To manage bruxism effectively, a range of therapeutic approaches and interventions are employed. Oral appliances such as mouthguards or splints are commonly used to protect teeth and reduce grinding forces, especially during sleep or stressful periods. Behavioral therapies, stress management techniques, and relaxation exercises complement these devices by addressing underlying psychological factors contributing to bruxism.

Recent advancements in dental technology and medical devices have introduced sophisticated biofeedback devices, wearable sensors, and digital monitoring tools. These tools aid in diagnosing bruxism patterns, assessing muscle activity, and monitoring occlusal forces, enabling a personalized and data-driven approach to treatment planning and monitoring.

Non-invasive interventions, pharmacological treatments such as muscle relaxants, botulinum toxin injections, or medications targeting underlying sleep disorders may be prescribed in specific cases. These interventions are often part of comprehensive bruxism management protocols developed collaboratively by dental professionals, sleep specialists, neurologists, and psychologists.

The market for bruxism management extends across dental clinics, healthcare facilities, and telehealth platforms, ensuring accessibility to comprehensive care for diverse patient populations. Educating patients about bruxism, its consequences, and available management options is crucial for promoting awareness and encouraging timely diagnosis and treatment adherence. By integrating innovative diagnostics, treatment modalities, digital health solutions, and collaborative care models, the Bruxism Management Market aims to improve patient outcomes, enhance quality of life, and advance oral healthcare practices globally.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Drugs Availability
    3. Market Snapshot, By Cause
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Global Bruxism Management Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Awareness and Diagnosis
        2. Technological Advancements
        3. Rising Stress Levels
      2. Restraints
        1. Limited Awareness in Emerging Markets
        2. High Cost of Treatment
      3. Opportunities
        1. Expansion in Emerging Markets
        2. Innovative Treatment Approaches
        3. Telemedicine and Digital Health Solutions
        4. Collaborative Partnerships
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Bruxism Management Market, By Type, 2021 - 2031 (USD Million)
      1. Diurnal Bruxism
      2. Nocturnal Bruxism
    2. Global Bruxism Management Market, By Drugs Availability, 2021 - 2031 (USD Million)
      1. Over-the-counter (OTC)
      2. Prescription
    3. Global Bruxism Management Market, By Cause, 2021 - 2031 (USD Million)
      1. Obstructive Sleep Apnea
      2. Sleep Paralysis
      3. Malocclusion
      4. Gastroesophageal Reflux Disease (GERD)
      5. Depression
      6. Anxiety
      7. Others
    4. Global Bruxism Management Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Institutional Sales
      2. Hospital
      3. Dental Clinic
      4. Retail Sales
      5. Drug Store
      6. Retail Store
      7. Supermarket
      8. Mail Order Pharmacies
    5. Global Bruxism Management Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Eli Lilly
      2. Cadila Pharmaceuticals
      3. GlaxoSmithKline plc
      4. Pfizer
      5. Akervall Technologies, Inc.
      6. Hoffmann-La Roche AG
      7. Mylan N.V.
      8. Teva Pharmaceutical Industries Ltd.
      9. Endo International plc
      10. Mayne Pharma
  7. Analyst Views
  8. Future Outlook of the Market